Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics and Pharmacodynamics of Torasemide

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The new loop diuretic torasemide belongs to the pyridine sulfonylurea class. It is well absorbed and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema. This is roughly double that of the ‘classical’ loop diuretic furosemide (frusemide) [26 to 65%].

Torasemide is highly bound to protein (99%) as is furosemide. The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide. Torasemide undergoes extensive hepatic metabolism; only 20% of the parent drug is recovered unchanged in the urine. For comparison only 10 to 20% of furosemide undergoes phase II metabolisation (to the glucuronide).

In chronic renal failure the renal clearance of torasemide decreased in proportion to the decrease of the patients’ glomerular filtration rate, whereas the total plasma clearance (3 times that of the renal clearance) appeared to be independent of renal function. As expected, the renal excretion of torasemide metabolites is significantly retarded in renal disease. The pharmacokinetics of torasemide are significantly influenced by liver disease. Total plasma clearance of torasemide was reduced to about half of that found in the control group, yielding an increase in elimination half-life. A greater than normal fraction of torasemide was recovered in the urine of patients with cirrhosis. In contrast, the kinetics of furosemide appeared to depend more on kidney function than on liver disease.

The pharmacodynamics of torasemide are principally the same as those reported from conventional loop diuretics due to their interference with one binding site in the thick ascending limb of Henle’s loop, the Na+:K+:2Cl− carrier. The maximum natriuretic effect of all loop diuretics amounts to about 3 mmol Na+/min. Members of this class differ, however, with respect to their intravenous potency or affinity for the receptor, respectively: bumetanide > piretanide > torasemide > furosemide.

So far, the only loop diuretic which has been shown to effectively lower high blood pressure is torasemide. This effect occurs at the low dose of 2.5 mg/day.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Besenfelder E. The determination of torasemide and metabolites in plasma by high-performance liquid chromatography. J Pharm Biomed Anal 1987; 5: 259–66.

    Article  PubMed  CAS  Google Scholar 

  2. March C, Farthing D, Wells B, et al. Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. J Pharm Sci 1990; 79: 453–7.

    Article  PubMed  CAS  Google Scholar 

  3. Weng ND, Mainquist D, Hulse JD, et al. HPLC determination of torsemide and three metabolites in human biological fluids. 9th Annual Meeting of the American Association of Pharmaceutical Scientists; 1994 Nov 6–10; San Diego. Pharm Res 1994; 11(10 Suppl.): 59.

    Google Scholar 

  4. Lesne M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittel Forschung 1988; 38(I): 160–3.

    PubMed  CAS  Google Scholar 

  5. Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers. Eur J Clin Pharmacol 1986; 31 Suppl.: 21–7.

    Article  PubMed  CAS  Google Scholar 

  6. Ambroes Y, Ronflette I, Dodion L. Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects. Eur J Clin Pharmacol 1986; 31 Suppl.: 1–7.

    Article  PubMed  CAS  Google Scholar 

  7. Lameire N, Dodion L. Acute and chronic effects of torasemide in healthy volunteers. Arzneimittel Forschung 1988; 38(I): 167–71.

    PubMed  CAS  Google Scholar 

  8. Neugebauer G, Besenfelder E, Moellendorff E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittel Forschung 1988; 38(I): 164–6.

    PubMed  CAS  Google Scholar 

  9. Knauf H, Spahn H, Rücker H-M, et al. The loop diuretic torasemide in renal failure: kinetics and dynamics. Prog Pharmacol Clin Pharmacol 1990; 8: 81–93.

    Google Scholar 

  10. Spahn H, Knauf H, Mutschler E. Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. Eur J Clin Pharmacol 1990; 39: 345–8.

    Article  PubMed  CAS  Google Scholar 

  11. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.

    Article  PubMed  CAS  Google Scholar 

  12. Barr WH, Smith HL, Karnes HT, et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers. Prog Pharmacol Clin Pharmacol 1990; 8: 15–28.

    CAS  Google Scholar 

  13. Barr WH, Smith HL, Karnes HT, et al. Torasemide doseproportionality of pharmacokinetics and pharmacodynamics. Prog Pharmacol Clin Pharmacol 1990; 8: 29–37.

    CAS  Google Scholar 

  14. Kramer WG. Effect of food on the pharmacokinetics and pharmacodynamics of torsemide. Am J Ther 1995; 2: 499–503.

    Article  PubMed  Google Scholar 

  15. Kramer WG. Lack of effect of cimetidine on torsemide pharmacokinetics and pharmacodynamics in healthy subjects. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publ. B.V., 1993: 361–4.

    Google Scholar 

  16. Moellendorff E, Neugebauer G. Pharmacokinetics of oral torasemide in patients with congestive heart failure. Prog Pharmacol and Clin Pharmacol 1990; 8: 73–9.

    Google Scholar 

  17. Vargo DL, Kramer WG, Black PK, et al. The pharmacodynamics of torsemide in patients with congestive heart failure. Clin Pharmacol Ther 1995a; 56: 48–54.

    Article  Google Scholar 

  18. Broekhuysen J, Deger F, Douchamps J, et al. Torasemide, a new potent diuretic: double-blind comparison with furosemide. Eur J Clin Pharmacol 1986; 31 Suppl.: 29–34.

    Article  PubMed  Google Scholar 

  19. Kult J, Ziegler J, Moellendorff E. Pharmacodynamics and -kinetics of torasemide and furosemide in patients with high grade renal failure after administration of high intravenous doses. Prog Pharmacol Clin Pharmacol 1990; 8: 239–48.

    Google Scholar 

  20. Krämer BK, Schwab A, Braun N, et al. Pharmacokinetics and metabolism of torasemide during acute and chronic dosing in end-stage renal disease. J Am Soc Nephrol 1992; 3: 285.

    Google Scholar 

  21. Gehr TWB, Rudy DW, Matzke GW, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 31–8.

    Article  PubMed  CAS  Google Scholar 

  22. Brunner G, Bergmann K, Häcker W, et al. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneimittel Forschung 1988; 38(I): 176–9.

    PubMed  CAS  Google Scholar 

  23. Gentilini P, La Villa G, Marra F, et al. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. J Hepatology 1996; 25: 481–90.

    Article  CAS  Google Scholar 

  24. Schwartz S, Brater DC, Pound D, et al. Bioavailability, pharmacokinetics and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993; 54: 90–7.

    Article  PubMed  CAS  Google Scholar 

  25. Rudy DW, Gehr TWB, Matzke GW, et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 39–47.

    Article  PubMed  CAS  Google Scholar 

  26. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57: 601–9.

    Article  PubMed  CAS  Google Scholar 

  27. Du Souich P, Proulx M, Perreault S. Pharmacokinetics of furosemide in healthy man. Prog Pharmacol Clin Pharmacol 1992; 9: 147–71.

    Google Scholar 

  28. Ward A, Heel RC. Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984; 28: 426–64.

    Article  PubMed  CAS  Google Scholar 

  29. Haak A, Neubert P. BM 02.021 (Carvedilol/Torasemide). In vitro protein binding of carvedilol in the presence of torasemide in man Pocumentation No. N 19, BM 02.015]. Boehringer Mannheim GmbH, 1987 Mar 23.

  30. Neubert P. Effect of torasemide on the protein binding of glibenclamide, digitoxin and benzbromarone in man [Documentation No. N 24, BM 02.015]. Boehringer Mannheim GmbH, 1990 Jan 19.

  31. Neubert P, Schaumann W. Determination of dissociation constant and binding capacity for the torasemide binding to human serum proteins [Documentation No. N 25, BM 02.015]. Boehringer Mannheim GmbH, 1990 Mar 14.

  32. Krämer BK, Ress KM, Möllendorff E, et al. Influenece of torasemide on serum level and renal elimination of digoxin in healthy volunteers. Prog Pharmacol Clin Pharmacol 1990; 8(1): 39–46.

    Google Scholar 

  33. Piesche L, Bölke T. Comparative clinical trial investigating possible interactions of torasemide (20mg o.d.) or furosemide (40mg o.d.) with phenprocoumon in patients with congestive heart failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publ. B.V, 1993: 267–70.

    Google Scholar 

  34. Möhrke W, Ullrich F. Metabolism of diuretics. In: Greger RF, Knauf H, Mutschler E, editors. Diuretics: handbook of experimental pharmacology. Vol. 117. Berlin: Springer, 1995: 173–200.

    Google Scholar 

  35. Boles Ponto LL, Schoenwald RD. Furosemide (frusemide): a pharmacokinetic-pharmacodynamic review, Part I. Clin Pharmacokinet 1990a; 18: 381–408.

    Article  Google Scholar 

  36. Boles Ponto LL, Schoenwald RD. Furosemide (frusemide): a pharmacokinetic-pharmacodynamic review, Part II. Clin Pharmacokinet 1990b; 18: 460–71.

    Article  Google Scholar 

  37. Brater DC. Clinical pharmacokinetics of diuretics in cardiac insufficiency. Prog Pharmacol Clin Pharmacol 1992; 9: 363–70.

    Google Scholar 

  38. Brater DC. Diuretic resistance: Mechanisms and therapeutic strategies. Cardiology 1994; 84 Suppl. 2: 57–67.

    Article  PubMed  Google Scholar 

  39. Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183–9.

    Article  PubMed  CAS  Google Scholar 

  40. Cook JA, Smith DE, Cornish LA, et al. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. Clin Pharmacol Ther 1988; 44: 487–500.

    Article  PubMed  CAS  Google Scholar 

  41. Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease: an update. J Pharmacokinet Biopharm 1989; 17: 1–47.

    PubMed  CAS  Google Scholar 

  42. Kramer WG. Pharmacokinetics and pharmacodynamics of torasemide in congestive heart failure. Cardiology 1994; 84 Suppl. 2: 108–14.

    Article  PubMed  Google Scholar 

  43. Marcantonio LA, Auld, WHR, Murdoch, WR, et al. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. Br J Clin Pharmacol 1983; 15: 245–52.

    Article  PubMed  CAS  Google Scholar 

  44. Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32: 572–8.

    Article  PubMed  CAS  Google Scholar 

  45. Mutschler E, Gilfrich HJ, Knauf H, et al. Pharmakokinetik von Triamteren bei Probanden und Patienten mit Leberund Nierenfunktionsstörungen. Klin Wochenschr 1983; 61: 883–91.

    Article  PubMed  CAS  Google Scholar 

  46. Knauf H, Gerok W, Mutschier E, et al. Disposition of xipamide in liver cirrhosis. Clin Pharmacol Ther 1990; 48: 628–32.

    Article  PubMed  CAS  Google Scholar 

  47. Knauf H, Mutschier E. Pharmacodynamic and -kinetic consideration on diuretics as a basis for differential therapy. Klin Wochenschr 1991; 69: 239–50.

    Article  PubMed  CAS  Google Scholar 

  48. Wittner M, Di Stefano A, Wangemann P, et al. How do loop diuretics act? Drugs 1991; 41 Suppl. 3: 1–13.

    Article  PubMed  CAS  Google Scholar 

  49. Greger R. Loop diuretics. In: Greger RF, Knauf H. Mutschier, editors. Handbook of experimental pharmacology. Vol. 117 Berlin: Springer, 1995: 221–74.

    Google Scholar 

  50. Knauf H, Mutschier E. Saluretic effect of the loop diuretic torasemide in chronic renal failure: interdependence of electrolyte excretion. Eur J Clin Pharmacol 1990; 39: 337–43.

    Article  PubMed  CAS  Google Scholar 

  51. Knauf H, Mutschier E. Pharmacodynamics and pharmacokinetics of xipamide in patients with normal and impaired kidney function. Eur J Clin Pharmacol 1984; 26: 513–20.

    Article  PubMed  CAS  Google Scholar 

  52. Knauf H, Mutschier E. Potassium loss induced by diuretics. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publ. B.V., 1993a: 253–6.

    Google Scholar 

  53. Knauf H. The role of low-dose diuretics in essential hypertension. J Cardiovasc Pharmacol 1993; 22 Suppl. 6: 1–7.

    Google Scholar 

  54. Baumgart P, Walger P, Eiff M, et al. Long-term efficacy and safety of torasemide in hypertension. Prog Pharmacol Clin Pharmacol 1990; 8: 169–81.

    Google Scholar 

  55. Achhammer I. Long-term efficacy and tolerance of torasemide in congestive heart failure. Prog Pharmacol Clin Pharmacol 1990; 8: 127–36.

    Google Scholar 

  56. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure. Shift in dose-response curves. Clin Pharmacol Ther 1980; 28: 182–6.

    Article  PubMed  CAS  Google Scholar 

  57. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22: 69–74.

    Article  PubMed  CAS  Google Scholar 

  58. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991; 41 Suppl. 3: 14–22.

    Article  PubMed  Google Scholar 

  59. Schrier RW. Pathogenessis of sodium and water retention in high and low output cardiac failure, cirrhosis, nephrotic syndrome, and pregnancy. N Engl J Med 1988; 319: 1065–72.

    Article  PubMed  CAS  Google Scholar 

  60. Seidin DW. Sodium balance and fluid volume in normal and edematous states. In: Seldin DW, Giebisch G, editors. The regulation of sodium and chloride balance. New York: Raven Press, 1990: 261–92.

    Google Scholar 

  61. Knauf H, Mutschier E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. In press.

  62. Keller E, Hoppe-Seyler G, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 1981; 20: 27–33.

    Article  PubMed  CAS  Google Scholar 

  63. Keller E, Hoppe-Seyler G, Mumm R, et al. Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin Pharmacol Ther 1982; 32: 442–9.

    Article  PubMed  CAS  Google Scholar 

  64. Knauf H, Mutschier E. Functional state of the nephron and diuretic dose-response: rationale for low-dose combination therapy. Cardiology 1994a; 84 Suppl. 2: 18–26.

    Article  PubMed  Google Scholar 

  65. Brater DC, Anderson SA, Brown-Cartwright D. Response to furosemide in chronic renal insufficiency: rationale for limited dose. Clin Pharmacol Ther 1986; 40: 134–9.

    Article  PubMed  CAS  Google Scholar 

  66. Knauf H, Spahn H, Mutschier E. The loop diuretic torasemide in chronic renal failure: pharmacokinetics and pharmacodynamics. Drugs 1991; 41 Suppl. 3: 23–34.

    Article  PubMed  Google Scholar 

  67. Eknoyan G. Diagnosis of disturbances. In: Seldin DW, Giebisch G, editors. The regulation of sodium and chloride balance. New York: Raven Press, 1990: 237–59.

    Google Scholar 

  68. Skorecki KL, Brenner BM. Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med 1982; 72: 323–38.

    Article  PubMed  CAS  Google Scholar 

  69. Knauf H, Mutschier E. Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide. Cardiology 1994b; 84 Suppl. 2: 87–98.

    Article  PubMed  Google Scholar 

  70. Knauf H, Mutschier E. Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy. Eur J Clin Pharmacol 1993b; 44 Suppl. 1: 63–8.

    Article  Google Scholar 

  71. Knauf H, Schollmeyer P, Verwiebe R. Diuretika bei nephrotischem Syndrom. Nieren Hochdruckkrankheiten 1996; 25: 287–92.

    Google Scholar 

  72. Schulz W, Dörfler A, Stiehl L, et al. Double-blind clinical trial investigating the efficacy and long-term tolerance of torasemide 200 mg p.o. compared with furosemide 500mg p.o. and placebo p.o. in patients with chronic renal failure on hemodialysis, a multicentre study. Prog Pharmacol Clin Pharmacol 1990; 8: 249–57.

    Google Scholar 

  73. Knauf H, Gerok W. Diuretika bei Leberzirrhose mit Aszites. Nieren Hochdruckkrankheiten 1996; 25: 300–9.

    Google Scholar 

  74. Strupp R, Boesken WH, Knauf H. Niedrigdosierte diuretische Kombinationstherapie bei Dialysepatienten. Nieren Hochdruckkrankheiten 1996; 25: 269–72.

    Google Scholar 

  75. McMahon FG. Management of essential hypertension: the once-a-day era. In: McMahon FG, editor. Diuretics: the thiazide, thiazidelike, and loop diuretics. 3rd ed. Mount Kisco (NY): Futura Publishing Company Inc., 1990: 297–378.

    Google Scholar 

  76. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension: experience with torasemide. Drugs 1991; 41 Suppl. 3: 80–91.

    Article  PubMed  Google Scholar 

  77. Schmieder RE, Rockstroh JK. Efficacy and tolerance of lowdose loop diuretics in hypertension. Cardiology 1994; 84 Suppl. 2: 36–42.

    Article  PubMed  Google Scholar 

  78. Roos JC, Boer P, Koomans HA, et al. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol 1981; 19: 107–12.

    Article  PubMed  CAS  Google Scholar 

  79. Cooper K. Diuretic treatment in hypertension. In: Benett WM, McCarron DA, editors. Pharmacotherapy of renal disease and hypertension: contemporary issues in nephrology. Vol. 17. New York: Churchill Livingstone, 1987: 197.

    Google Scholar 

  80. Guedon J, Chaignon M, Lucsko M. Diuretics as antihypertensive drugs. Kidney Int 1988; 34 Suppl. 25: 177–80.

    Google Scholar 

  81. Mosbacher J. Untersuchungen zum möglichen vasorelaxierenden Effekt des Schleifendiuretikums Torasemid und dessen antihypertensiver Potenz im Vergleich zu anderen Diuretika [thesis]. Heidelberg: University of Heidelberg, 1993: 1–124.

    Google Scholar 

  82. Knauf H, Mutschier E. Niedrigdosierte Diuretika-Therapie der essentiellen Hypertonie. Nieren-Hochdruckkr 1996; 25: 245–9.

    Google Scholar 

  83. Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf 1996; 14: 104–20.

    Article  PubMed  CAS  Google Scholar 

  84. Knauf H, Mutschier E. Niedrigdosierte Diuretika-Therapie der essentiellen Hypertonie. Nieren Hochdruckkrankheiten 1996; 25: 245–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I, St Bernnard-Krankenhaus, 31134, Hildesheim, Germany

    Heinrich Knauf

  2. Pharmakologisches Institut für Naturwissenschaftler, Johann Wolfgang Goethe-Universität, Frankfurt/Main, Germany

    Ernst Mutschler

Authors
  1. Heinrich Knauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernst Mutschler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knauf, H., Mutschler, E. Clinical Pharmacokinetics and Pharmacodynamics of Torasemide. Clin Pharmacokinet 34, 1–24 (1998). https://doi.org/10.2165/00003088-199834010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199834010-00001

Keywords

Search

Navigation